Literature DB >> 16378532

The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.

Stephen Birch1, Amiram Gafni.   

Abstract

It has been suggested that scepticism among decision-makers about using cost-effectiveness analysis (CEA) is caused in part by the low level of the cost-effectiveness "thresholds" in the economic evaluation literature. This has led Ubel and colleagues to call for higher threshold values of US$200,000 or more per quality-adjusted life-year. We show that these arguments fail to identify the objective of CEA and hence do not consider whether or how the threshold relates to this objective. We show that incremental cost-effectiveness ratios (ICERs) cannot be used to identify an efficient use of resources--the "biggest bang for the bucks"--allocated to health care. On the contrary, the practical consequence of using the ICER approach is shown to be an increase in health care expenditures, or "bigger bucks for making a bang", without any evidence of the bang being bigger (i.e. that this leads to an increase in benefits to the population). We present an alternative approach that provides an unambiguous method of determining whether a new intervention leads to an increase in health gains from whatever resources are to be made available to health care decision-makers.

Entities:  

Mesh:

Year:  2006        PMID: 16378532     DOI: 10.1258/135581906775094235

Source DB:  PubMed          Journal:  J Health Serv Res Policy        ISSN: 1355-8196


  18 in total

1.  [The distribution of health resources: a hybrid model of equality and maximization].

Authors:  Yanick Farmer
Journal:  Can J Public Health       Date:  2012 Mar-Apr

2.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 3.  Information created to evade reality (ICER): things we should not look to for answers.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Building bridges between academic research and policy formulation: when costing less means costing more.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 6.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

Review 7.  Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules.

Authors:  Samuel D Shillcutt; Damian G Walker; Catherine A Goodman; Anne J Mills
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.

Authors:  A T Newall; M Jit; R Hutubessy
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

9.  Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings.

Authors:  Sarah E Rutstein; Joan T Price; Nora E Rosenberg; Stuart M Rennie; Andrea K Biddle; William C Miller
Journal:  Glob Public Health       Date:  2016-05-04

Review 10.  Cost-Effectiveness of Deep Brain Stimulation With Movement Disorders: A Systematic Review.

Authors:  Tho Thi Hai Dang; David Rowell; Luke B Connelly
Journal:  Mov Disord Clin Pract       Date:  2019-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.